Sagefield Capital LP Takes $4.86 Million Position in Atrion Co. (NASDAQ:ATRI)

Sagefield Capital LP bought a new position in shares of Atrion Co. (NASDAQ:ATRI) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 10,740 shares of the medical instruments supplier’s stock, valued at approximately $4,859,000. Sagefield Capital LP owned 0.61% of Atrion as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ATRI. BNP Paribas Financial Markets grew its stake in shares of Atrion by 3.6% in the 1st quarter. BNP Paribas Financial Markets now owns 723 shares of the medical instruments supplier’s stock worth $335,000 after purchasing an additional 25 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in Atrion by 12.7% during the second quarter. Principal Financial Group Inc. now owns 681 shares of the medical instruments supplier’s stock worth $308,000 after buying an additional 77 shares in the last quarter. Quadrant Capital Group LLC acquired a new position in Atrion in the fourth quarter worth approximately $36,000. Oppenheimer Asset Management Inc. increased its holdings in shares of Atrion by 12.0% in the first quarter. Oppenheimer Asset Management Inc. now owns 1,105 shares of the medical instruments supplier’s stock valued at $512,000 after buying an additional 118 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of Atrion during the 2nd quarter valued at $54,000. 66.19% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on Atrion in a report on Thursday, September 19th. They issued a “sell” rating on the stock.

Atrion Stock Performance

NASDAQ ATRI opened at $459.92 on Tuesday. Atrion Co. has a 1 year low of $274.98 and a 1 year high of $503.24. The company has a market cap of $809.46 million, a PE ratio of 43.23 and a beta of 0.69. The stock’s 50-day moving average price is $459.06 and its two-hundred day moving average price is $446.19.

Atrion (NASDAQ:ATRI) last released its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter. Atrion had a net margin of 10.60% and a return on equity of 7.75%. The business had revenue of $48.77 million for the quarter.

About Atrion

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.